+91 - 830 - 3146878
We evaluate the efficacy study of herbomineral drug LAS02 in breast cancer patients who admitted in three city (Lucknow , Noida and Delhi) of Lavanya Ayurvedic Hospital & Research Centre For Cancer, Hepatitis and AIDS. The study was conducted after getting ethical clearance. Total 98 patients were enrolled in three city of Lavanaya hospital (62 patients in lucknow, 13 patient in Noida and 23 patients in Delhi). These patients were suffering only from breast cancer not any other diseases. All patients having medication ayuredic herbomineral drug LAS 02 for more than one month treatment. After obtaining prior consent form these patients, venous blood samples was collected from the subjects before and after treatment with herbomineral drug LAS02 and measured the hematological and biochemical examinations along with breast cancer biomarker and tumor size.
A statistically ( 52%, 72% 42% 76% and CA 15.3,70%) significant reduction of tumor size (mm) and breast cancer bio marker CA 15.3 in patients as compared to before treated patients There was significant decreased ESR levels in patients after treatment with LAS 02 more than one month as compared with before treatment. A significant reduction of hepatic enzymes ( ALP and LDH ) in patients after treatment with drug. These findings suggested that LAS02 is most effective medicine for prevention and cancer diseases.
The study was conducted after getting ethical clearance from Institutional human ethic committee. Total 98 cancer patients with age (25-65 years) were enrolled in three city of Lavanya Ayurvedic Hospital and Research Centre. These patients were only suffering from breast cancer not from any organic diseases. After obtaining prior consent form, venous blood samples was collected from the subjects before (pre) and after treatment (post) with herbomineral drug LAS02 under aseptic condition. The drug was given to these patients for two months. After collection of blood sample, serum and plasma were separated by centrifugation at 4000 rpm for 10 min. at room temperature for measurement of hematological, biochemical parameters along with CA 15.3 biomarker and total tumor size (mm) in pre and post treated patients.
All hematological and biochemistry parameters hemoglobin (Hb), alkaline phosphate (ALP), Serum glutamate oxaloacetate transminase (SGOT), Serum glutamate pyurvate transminase (SGPT) parameters were measured by fully automatic cell counter and clinical chemistry analyzer.
LDH activity was measured by kit according to protocol provided by supplier (Tranasia biomedical). The activity was expressed as an IU/ml.
Levels of serum CA-15.3 (Fujirebio Diagnostics, Malvern, PA), was determined using a quantitative sandwich enzyme immunoassay according to manufacturer protocol.
Resulting data were expressed mean ± SD. Percentage parenthesis was observed between pre vs post treatment with LAS02 drug in breast cancer patients.
We measured the total tumor size in pre and post treated patients based on tumor size value I and it was found that a significant about 54% (n=7), 72% (n=5), 42%, 43% and 76% and completely fineshed tumor size in patients treated group. This parameters calculated individual tumor size of patient. A significant (71% )reduction of CA 15.3 biomarker in patient post treated group in comparison to patient pre treated group. VIEW CHART
ESR level was also found significant ( 14%; 32% and 45%) decreased in the patients after treatment with LAS02 in comparison to pre treatment. VIEW CHART
There were slightly increased percentage in Hb(%), hematocrit and RBC levels in patient treated group as compared with patient pre treated group. VIEW CHART
There were significant(11.6% ,60%; and45%) reduction of LDH and ALP enzyme activities (36.3% ,55%)in patients post treated group in comparison to patient pre treated group. VIEW CHART
On the basis of these findings it is suggested that the herbomineral drug LAS02 is most effective medicine for prevention of breast cancer diseases.
The purpose of this study was to evaluate the acute oral toxicity study of LAS02 in female Sprague Dawley rat model. [...]
The purpose of this study was to evaluate the maximum tolerated dose of LAS02 in Sprague dawley female rat. [...]
The aim of this study was to evaluate the maximum tolerated dose of LAS02 in female Sprague Dawley rat. [...]